Abstract
Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl(+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit(+) secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response lasting for more than 5 months was observed. Sequence analysis of exons 2, 8, 10, 11, and 17 of the c-Kit receptor did not reveal structural alterations as previously described in a subset of AML cases. This is the first report of complete remission achieved upon administration of imatinib mesylate in a patient with highly refractory, secondary AML.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anemia, Refractory / drug therapy*
-
Anemia, Refractory, with Excess of Blasts / drug therapy*
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzamides
-
Bone Marrow / pathology
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Disease Progression
-
Drug Resistance, Neoplasm
-
Enzyme Inhibitors / therapeutic use*
-
Exons / genetics
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / enzymology
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / pathology
-
Male
-
Middle Aged
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / genetics
-
Neoplastic Stem Cells / pathology
-
Piperazines / therapeutic use*
-
Proto-Oncogene Proteins c-kit / drug effects*
-
Proto-Oncogene Proteins c-kit / genetics
-
Pyrimidines / therapeutic use*
-
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors
-
Receptors, Platelet-Derived Growth Factor / genetics
-
Recurrence
-
Remission Induction
-
Salvage Therapy
Substances
-
Antineoplastic Agents
-
Benzamides
-
Enzyme Inhibitors
-
Neoplasm Proteins
-
Piperazines
-
Pyrimidines
-
Cytarabine
-
Imatinib Mesylate
-
Proto-Oncogene Proteins c-kit
-
Receptors, Platelet-Derived Growth Factor
-
Daunorubicin